Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better InvestmentSeeking Alpha • 06/06/25
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOCNBC • 06/03/25
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug raceMarket Watch • 06/02/25
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual MeetingGlobeNewsWire • 05/27/25
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 ShotsZacks Investment Research • 05/21/25
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.Investors Business Daily • 05/20/25
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology ExpansionBenzinga • 05/05/25
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial OfficerGlobeNewsWire • 05/05/25
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged TodayThe Motley Fool • 04/25/25
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025GlobeNewsWire • 04/24/25
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?Investors Business Daily • 04/23/25
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025GlobeNewsWire • 04/22/25
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?Zacks Investment Research • 04/15/25
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.Investors Business Daily • 04/10/25